Senseonics Holdings (SENS) AI Stock Analysis

• Market Cap: $369.05M
• Dividend Yield: N/A
• Average Volume (3M): 5.04M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.64
• Revenue Growth: 5.94%
• EPS Growth: 25.16%
• Country: US
• Employees: 117
• Sector: Healthcare
• Sector Strength: 49
• Industry: Medical - Devices
• EPS (TTM): -0.02
• Shares Outstanding: 814,680,900
• 10 Day Avg. Volume: 4,600,304
• 30 Day Avg. Volume: 5,044,481
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 11.14
• Enterprise Value/Gross Profit: 56.39
• Enterprise Value/Ebitda: -5.10
• 1Y Price Target: $1.28
• Price Target Upside: 184.44% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8

• Rating: 46 Neutral
• Price Target: $0.50 ▲(11.11% Upside)

Senseonics Holdings' overall stock score reflects significant financial challenges, with ongoing losses and high leverage being major concerns. Despite positive developments in earnings call and corporate events, the stock's technical indicators and valuation suggest caution.

Positive Factors

Financial Performance

The company's updated financial model reflects higher expectations for revenue growth, with significant increases in projected revenues for 2026 and 2027.

Product Innovation

Senseonics is poised for accelerated growth following the U.S. launch of Eversense 365, its year-long implantable CGM.

Strategic Partnerships

Abbott recently took a 5% stake in Senseonics, which came with a right of first negotiation and quarterly updates on Senseonics’ R&D programs.

Negative Factors

Market Competition

A meaningful cohort of PWDs see an implanted sensor as acceptable, suggesting an opportunity among current CGM users who are frustrated with their present CGM.

Operational Challenges

Senseonics will need a large, high-touch salesforce and marketing teams to be successful in taking meaningful share from legacy systems or to expand the CGM-using population.

Senseonics Holdings Business Overview & Revenue Model

Company Description

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

How the Company Makes Money

Senseonics generates revenue primarily through the sale of its Eversense CGM systems, including the implantable sensors and the associated mobile application that allows users to monitor their glucose levels. The company's revenue model is driven by the initial sale of the devices to healthcare providers, who then supply them to patients. Additionally, Senseonics benefits from recurring revenue through the sale of replacement sensors as they need to be replaced periodically. The company has established partnerships with various healthcare providers and payers to facilitate patient access to its products, which is a significant factor contributing to its earnings. Furthermore, as diabetes management becomes increasingly important, Senseonics may also explore collaborations with pharmaceutical companies and other medical technology firms to expand its market reach and enhance its product offerings.

Senseonics Holdings Financial Statement Overview

Summary

Senseonics Holdings faces significant financial challenges. Despite revenue growth, profitability and cash flow remain major concerns. High leverage and negative equity in certain periods highlight financial instability. The company needs to improve operational efficiency and reduce reliance on debt.

Income Statement

Senseonics Holdings shows a mixed performance in its income statement. The company has experienced revenue growth, with a 14.49% increase in the TTM period. However, profitability remains a significant challenge, as evidenced by negative net profit margins and EBIT margins. The gross profit margin has improved over time, but the company continues to operate at a loss, indicating ongoing operational inefficiencies.

Balance Sheet

The balance sheet reflects a high debt-to-equity ratio, indicating significant leverage, which poses a financial risk. The company has negative stockholders' equity in some periods, highlighting financial instability. Return on equity is negative, further emphasizing the company's struggle to generate profits from its equity base. The equity ratio is low, suggesting a reliance on debt financing.

Cash Flow

Cash flow analysis reveals some positive aspects, such as a slight improvement in free cash flow growth. However, the company has negative operating cash flow, which is concerning. The free cash flow to net income ratio is slightly above 1, indicating that the company is generating some cash relative to its net losses, but overall cash flow remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	27.11M	22.47M	22.39M	16.39M	13.68M	4.95M
Gross Profit	5.36M	533.00K	3.09M	2.73M	-811.00K	-17.37M
EBITDA	-59.17M	-68.70M	-48.01M	161.81M	-284.51M	-157.86M
Net Income	-69.19M	-78.62M	-60.39M	142.12M	-302.47M	-175.17M
Balance Sheet
Total Assets	100.44M	100.44M	138.22M	177.67M	198.93M	35.92M
Cash, Cash Equivalents and Short-Term Investments	74.91M	74.60M	109.46M	144.01M	129.91M	18.00M
Total Debt	61.05M	61.05M	47.78M	75.38M	64.21M	62.70M
Total Liabilities	79.34M	116.99M	64.77M	180.25M	384.46M	180.00M
Stockholders Equity	21.10M	-16.55M	73.45M	-2.58M	-185.53M	-144.08M
Cash Flow
Free Cash Flow	-59.69M	-62.70M	-70.51M	-66.62M	-56.29M	-67.60M
Operating Cash Flow	-59.39M	-60.47M	-70.16M	-66.31M	-56.08M	-67.42M
Investing Cash Flow	73.33M	32.84M	89.71M	26.88M	-148.75M	-181.00K
Financing Cash Flow	38.00M	26.83M	20.37M	41.76M	220.08M	-10.13M

Senseonics Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SENS, the sentiment is Negative. The current price of 0.45 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.49, and below the 200-day MA of 0.60, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 39.68 is Neutral, neither overbought nor oversold. The STOCH value of 26.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SENS.

Senseonics Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	74 Outperform	$29.14B	55.25	22.83%	―	9.30%	-14.95%
LIVN	61 Neutral	$3.11B	30.62	-17.87%	―	8.57%	-1154.64%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
OM	50 Neutral	$243.82M	―	-87.65%	―	2.47%	56.93%
TNDM	49 Neutral	$863.54M	―	-111.91%	―	25.84%	-47.67%
SENS	46 Neutral	$369.05M	―	-102.61%	―	5.94%	25.16%
NNOX	40 Underperform	$241.02M	―	-32.87%	―	17.36%	9.38%

Senseonics Holdings Corporate Events

Senseonics Expands Debt Facility with Hercules Capital

On September 3, 2025, Senseonics Holdings entered into an Amended Loan Agreement with Hercules Capital, expanding their non-dilutive debt facility to $100 million to fund their commercial organization. This agreement includes an initial term loan of $35 million and additional tranches, with the loans maturing on September 3, 2029. Concurrently, Senseonics signed a Memorandum of Understanding with Ascensia Diabetes Care to transition the commercialization and distribution of Eversense 365 back to Senseonics by January 1, 2026. This strategic move aims to unify the Eversense business under Senseonics, potentially accelerating growth and improving operational efficiency. Brian Hansen, Ascensia’s President of CGM, will join Senseonics as Chief Commercial Officer to lead these efforts.